Get startedLog in
    Picture of Merck & Co logo

    MRK — Merck & Co News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Brief: Merck Enters Into Exclusive Global License Agreement With Scibrunch Therapeutics For Spr2015, An Investigational Oral Kras G12d (On) Inhibitor

    Picture of Merck & Co logoMerck & Co
    28/09/2026 11:46
    BRIEF-Merck Enters Into Exclusive Global License Agreement With Scibrunch Therapeutics For Spr2015, An Investigational Oral Kras G12d (On) Inhibitor
    Sept 28 (Reuters) - Merck & Co Inc MRK.N:
    • MERCK ENTERS INTO EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH SCIBRUNCH THERAPEUTICS FOR SPR2015, AN INVESTIGATIONAL ORAL KRAS G12D (ON) INHIBITOR
    • MERCK & CO - DEAL INCLUDES $400 MILLION UPFRONT, TOTAL POTENTIAL VALUE $2.13 BILLION; DEAL CLOSED
    • MERCK & CO - TO RECORD $400 MILLION PRE-TAX CHARGE, $0.13 PER SHARE, IN Q3 2026
    • MERCK & CO INC: UNDER AGREEMENT, SCIBRUNCH GRANTED CO EXCLUSIVE RIGHTS TO DEVELOP, MANUFACTURE & COMMERCIALIZE SPR2015 WORLDWIDE
    Source text: ID:nBw7Fz6F2a
    Further company coverage: MRK.N

     ((Reuters.Briefs@thomsonreuters.com;;))

    Recent news on Merck & Co

    See all news